Loading...
•
Mar 31, 2021
Insmed Q1 2021 Earnings Report
Insmed reported first quarter 2021 financial results and provided a business update.
Key Takeaways
Insmed reported a strong start to 2021, securing approval of ARIKAYCE in Japan, demonstrating steady ARIKAYCE performance in the U.S., and advancing its European launch. The company continues to enroll patients in clinical trials and is working to advance TPIP to Phase 2 clinical development.
ARIKAYCE approved in Japan for NTM lung disease caused by MAC.
ARIKAYCE European launch underway with commercial sales in Germany and the Netherlands.
Enrollment progresses in Phase 3 ASPEN study of Brensocatib in patients with Bronchiectasis and in post-marketing ARISE and ENCORE studies of ARIKAYCE in frontline NTM Lung Disease caused by MAC.
Treprostinil Palmitil Inhalation Powder (TPIP) advancing to Phase 2 development in Pulmonary Arterial Hypertension (PAH).
Insmed
Insmed
Forward Guidance
Insmed plans to continue to invest in U.S. commercialization of ARIKAYCE, clinical trial activities, and launch activities for ARIKAYCE in initial European countries and in Japan.
Positive Outlook
- U.S. commercialization of ARIKAYCE
- Advancement of the frontline clinical trial program for ARIKAYCE (ARISE and ENCORE)
- Advancement of the Phase 3 ASPEN study of brensocatib in patients with bronchiectasis
- Advancement of clinical development of TPIP
- Advancement of our earlier-stage research pipeline